Navigation Links
Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
Date:10/21/2008

NATICK, Mass., Oct. 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2008, as well as guidance for net sales and earnings per share (EPS) for the fourth quarter of 2008.

Third quarter highlights:

-- Reported net sales of $1.978 billion and adjusted EPS of $0.16

-- Maintained U.S. drug-eluting stent (DES) market leadership

-- Achieved worldwide cardiac rhythm management (CRM) sales growth of 11

percent

-- Launched the COGNIS(TM) CRT-D and TELIGEN(TM) ICD devices in the U.S.

-- Received FDA approval for the TAXUS(R) Express2(TM) Atom(TM)

Paclitaxel-Eluting Coronary Stent System, the first DES for small

vessels

-- Launched the PROMUS(TM) Everolimus-Eluting Coronary Stent System in the

U.S.

-- Generated $638 million of operating cash flow

-- Paid down $500 million of debt

-- Reduced SG&A and R&D expenses by $128 million from prior year

"For the second consecutive quarter, we maintained our strong U.S. DES market share leadership of 45 percent, even though there are now four competing companies," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "This clearly demonstrates the power of our unique two-drug platform. In our CRM business, we launched COGNIS and TELIGEN -- the world's smallest and thinnest high-energy CRT-D and ICD devices -- to a very positive reception from physicians. We have now received FDA approval for our TAXUS Atom and TAXUS(R) Liberte(R) stent systems, and we are looking forward to additional approvals, including our Apex(TM) balloon catheter, Carotid WALLSTENT(R) and Express(R) SD Renal Stent BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS

(Unaudited)

Nine Months Ended

September 30,

In millions, except per share data 2008 2007

Net sales $6,048 $6,204

Cost of products sold 1,839 1,706

Gross profit 4,209 4,498

Operating expenses

Selling, general and administrative

expenses 1,925 2,205

Research and development expenses 749 835

Royalty expense 144 151

Amortization expense 410 467

Intangible asset impairment charges 155

Purchased research and development 21 72

Litigation-related charges 334

Restructuring charges 59

Acquisition-related milestone (250)

Gain on divestitures (250)

Loss on assets held for sale 352

3,297 4,082

Operating income 912 416

Other income (expense):

Interest expense (361) (433)

Other, net (57) 44

Income before income taxes 494 27

Income tax expense 136 64

Net income (loss) $358 $(37)

Net income (loss) per common share -

basic $0.24 $(0.02)

Net income (loss) per common share -

assuming dilution $0.24 $(0.02)

Weighted average shares outstanding -

basic 1,497.5 1,485.5

Weighted average shares outstanding -

assuming dilution 1,504.4 1,485.5

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

Nine Months Ended Nine Months Ended

September 30, 2008 September 30, 2007

Impact per Net Impact per

Net diluted (loss) diluted

In millions, except per share data income share income share

GAAP results $358 $0.24 $(37) $(0.02)

Non-GAAP adjustments:

Acquisition-related (credits)

charges (164) (0.11) 104 0.07*

Restructuring-related charges 72 0.05

Litigation-related charges 266 0.18

Divestiture-related (gains) losses (78) (0.06) 352 0.23*

Intangible asset impairment charges 129 0.09

Amortization expense 314 0.21 383 0.25*

Adjusted results $897 $0.60 $802 $0.53

* Assumes dilution of 14.5 million shares for the nine months ended

September 30, 2007 for all or a portion of these non-GAAP adjustments.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (CONT.)

(Unaudited)

Nine Months Ended

September 30,

2008 2007

Acquisition-related (credits)

charges:

Acquisition-related milestone $(250)

Purchased research and development 21 $72

Integration costs (a) 34

Fair value adjustment for the sharing

of proceeds feature of the Abbott

Laboratories stock purchase (b) 8

(229) 114

Less: Income tax expense (benefit) (d) 65 (10)

Acquisition-related charges, net of tax $(164) $104

Restructuring-related charges:

Restructuring-related charges (c) $99

Less: Income tax benefit (d) (27)

Restructuring-related charges, net of tax $72

Litigation-related charges:

Litigation-related charges $334

Less: Income tax benefit (d) (68)

Litigation-related charges, net of tax $266

Divestiture-related (gains) losses:

Gain on divestitures $(250)

Net loss on sale of investments (b) 80

Loss on assets held for sale $352

(170) 352

Less: Income tax expense (d) 92

Divestiture-related (gains) losses, net of tax $(78) $352

Intangible asset impairment charges:

Intangible asset impairment charges $155

Less: Income tax benefit (d) (26)

Intangible asset impairment charges, net of tax $129

Amortization expense:

Amortization expense $410 $467

Less: Income tax benefit (d) (96) (84)

Amortization expense, net of tax $314 $383

(a) Recorded expenses of $25 million to selling, general and

administrative expenses, $6 million to cost of products sold, and $3

million to research and development expenses.

(b) Recorded to other, net.

(c) Recorded $11 million to cost of products sold; $24 million to selling,

general and administrative expenses; $5 million to research and

development expenses; and $59 million to restructuring charges.

(d) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item in

accordance with FASB Interpretation No. 18, "Accounting for Income

Taxes in Interim Periods."

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

September 30, December 31,

In millions 2008 2007

(Unaudited)

Assets

Current assets:

Cash and cash equivalents $1,734 $1,452

Trade accounts receivable, net 1,355 1,502

Inventories 854 725

Deferred income taxes 995 679

Assets held for sale 1,099

Other current assets 349 464

Total current assets 5,287 5,921

Property, plant and equipment, net 1,716 1,735

Investments 120 317

Other assets 165 157

Intangible assets, net 22,538 23,067

$29,826 $31,197

Liabilities and Stockholders' Equity

Current liabilities:

Short-term debt $7 $256

Accounts payable and accrued expenses 3,168 2,680

Liabilities associated with assets

held for sale 39

Other current liabilities 363 275

Total current liabilities 3,538 3,250

Long-term debt 6,767 7,933

Deferred income taxes 2,324 2,284

Other long-term liabilities 1,507 2,633

Stockholders' equity 15,690 15,097

$29,826 $31,197

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Change

As

Three Months Ended Reported Constant

September 30, Currency Currency

In millions 2008 2007 Basis Basis

DOMESTIC $1,125 $1,111 1% 1%

EMEA 472 426 11% 4%

INTER-CONTINENTAL 369 378 (2%) (8%)

INTERNATIONAL 841 804 5% (2%)

DIVESTED BUSINESSES 12 133 N/A N/A

WORLDWIDE $1,978 $2,048 (3%) (6%)

Change

As

Three Months Ended Reported Constant

September 30, Currency Currency

In millions 2008 2007 Basis Basis

INTERVENTIONAL CARDIOLOGY $694 $740 (6%) (9%)

PERIPHERAL INTERVENTION 143 147 (3%) (6%)

CARDIOVASCULAR 837 887 (5%) (9%)

NEUROVASCULAR 88 81 7% 2%

PERIPHERAL EMBOLIZATION 23 25 (3%) (6%)

NEUROVASCULAR 111 106 5% 0%

CARDIAC RHYTHM MANAGEMENT 572 517 11% 8%

ELECTROPHYSIOLOGY 40 36 10% 8%

CARDIAC RHYTHM MANAGEMENT 612 553 11% 8%

ENDOSCOPY 238 217 9% 6%

UROLOGY 109 100 9% 8%

ENDOSURGERY 347 317 9% 7%

NEUROMODULATION 59 52 15% 15%

DIVESTED BUSINESSES 12 133 N/A N/A

WORLDWIDE $1,978 $2,048 (3%) (6%)

Growth rates are based on actual, non-rounded amounts.

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Change

As

Nine Months Ended Reported Constant

September 30, Currency Currency

In millions 2008 2007 Basis Basis

DOMESTIC $3,330 $3,397 (2%) (2%)

EMEA 1,509 1,352 12% 1%

INTER-CONTINENTAL 1,147 1,048 9% (1%)

INTERNATIONAL 2,656 2,400 11% 0%

DIVESTED BUSINESSES 62 407 N/A N/A

WORLDWIDE $6,048 $6,204 (3%) (7%)

Change

As

Nine Months Ended Reported Constant

September 30, Currency Currency

In millions 2008 2007 Basis Basis

INTERVENTIONAL CARDIOLOGY $2,158 $2,257 (4%) (9%)

PERIPHERAL INTERVENTION 452 445 1% (3%)

CARDIOVASCULAR 2,610 2,702 (3%) (8%)

NEUROVASCULAR 272 260 4% (3%)

PERIPHERAL EMBOLIZATION 68 71 (3%) (6%)

NEUROVASCULAR 340 331 3% (4%)

CARDIAC RHYTHM MANAGEMENT 1,715 1,580 9% 5%

ELECTROPHYSIOLOGY 116 109 7% 4%

CARDIAC RHYTHM MANAGEMENT 1,831 1,689 8% 4%

ENDOSCOPY 710 637 11% 6%

UROLOGY 318 295 8% 6%

ENDOSURGERY 1,028 932 10% 6%

NEUROMODULATION 177 143 24% 23%

DIVESTED BUSINESSES 62 407 N/A N/A

WORLDWIDE $6,048 $6,204 (3%) (7%)

Growth rates are based on actual, non-rounded amounts.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

Q3 2008 Net Sales as compared to Q3 2007

Estimated

Change Impact

As Reported Constant of Foreign

Currency Basis Currency Basis Currency

In millions

DOMESTIC $14 $14

EMEA 46 15 31

INTER-CONTINENTAL (9) (32) 23

INTERNATIONAL 37 (17) 54

DIVESTED BUSINESSES (121) (121)

WORLDWIDE $(70) $(124) $54

Q3 2008 Net Sales as compared to Q3 2007

Estimated

Change Impact

In millions As Reported Constant of Foreign

Currency Basis Currency Basis Currency

INTERVENTIONAL CARDIOLOGY $(46) $(68) $22

PERIPHERAL INTERVENTIONS (4) (9) 5

CARDIOVASCULAR (50) (77) 27

NEUROVASCULAR 7 3 4

PERIPHERAL EMBOLIZATION (2) (3) 1

NEUROVASCULAR 5 5

CARDIAC RHYTHM MANAGEMENT 55 42 13

ELECTROPHYSIOLOGY 4 3 1

CARDIAC RHYTHM MANAGEMENT 59 45 14

ENDOSCOPY 21 14 7

UROLOGY 9 8 1

ENDOSURGERY 30 22 8

NEUROMODULATION 7 7

DIVESTED BUSINESSES (121) (121)

WORLDWIDE $(70) $(124) $54

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

Q3 2008 YTD Net Sales as compared to Q3 2007

Estimated

Change Impact

As Reported Constant of Foreign

Currency Basis Currency Basis Currency

In millions

DOMESTIC $(67) $(67)

EMEA 157 9 148

INTER-CONTINENTAL 99 (6) 105

INTERNATIONAL 256 3 253

DIVESTED BUSINESSES (345) (350) 5

WORLDWIDE $(156) $(414) $258

Q3 2008 YTD Net Sales as compared to Q3 2007

Estimated

Change Impact

In millions As Reported Constant of Foreign

Currency Basis Currency Basis Currency

INTERVENTIONAL CARDIOLOGY $(99) $(202) $103

PERIPHERAL INTERVENTIONS 7 (14) 21

CARDIOVASCULAR (92) (216) 124

NEUROVASCULAR 12 (6) 18

PERIPHERAL EMBOLIZATION (3) (7) 4

NEUROVASCULAR 9 (13) 22

CARDIAC RHYTHM MANAGEMENT 135 72 63

ELECTROPHYSIOLOGY 7 4 3

CARDIAC RHYTHM MANAGEMENT 142 76 66

ENDOSCOPY 73 38 35

UROLOGY 23 17 6

ENDOSURGERY 96 55 41

NEUROMODULATION 34 34

DIVESTED BUSINESSES (345) (35. We see these recent approvals as evidence of the ongoing progress we are making in quality and toward removing the new product approval restrictions placed on us by the FDA, which we believe will be completed in the near future. Also during the quarter, we continued to improve our operating cash flow, pay down debt and maintain a strong balance sheet."

Net sales for the third quarter of 2008 were $1.978 billion, including sales from divested businesses of $12 million, as compared to sales of $2.048 billion for the third quarter of 2007, including sales from divested businesses of $133 million.

Worldwide sales of the Company's drug-eluting coronary stent systems for the third quarter of 2008 were $396 million, as compared to $448 million for the third quarter of 2007. U.S. sales of these systems were $209 million, as compared to $240 million. International sales of these systems were $187 million, as compared to $208 million. Worldwide sales of coronary stent systems were $446 million for the third quarter of 2008, as compared to $507 million for the third quarter of 2007. U.S. sales of these systems were $228 million, as compared to $268 million. International sales of these systems were $218 million, as compared to $239 million.

Worldwide sales of the Company's CRM products for the third quarter of 2008 were $572 million, which included $423 million of implantable cardioverter defibrillator (ICD) sales, as compared to worldwide CRM sales of $517 million for the third quarter of 2007, which included $372 million of ICD sales. U.S. CRM product sales were $377 million, which included $291 million of ICD sales, as compared to $343 million, which included $261 million of ICD sales. International CRM sales were $195 million, which included $132 million of ICD sales, as compared to $174 million, which included $111 million of ICD sales.

Reported net loss for the third quarter of 2008 was $62 million, or $0.04 per share. Reported results inclu0) 5

WORLDWIDE $(156) $(414) $258

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION

ESTIMATED NON-GAAP NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

Q4 2008 Estimate Q4 2008 Estimate

(Low) (High)

GAAP results $0.10 $0.15

Estimated restructuring-related charges 0.01 0.01

Estimated amortization expense 0.07 0.07

Adjusted results $0.18 $0.23

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's condensed consolidated financial statements presented on a GAAP basis; the Company discloses certain non-GAAP measures that exclude certain amounts, including non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income and the GAAP measure most comparable to non-GAAP net income per diluted share is GAAP net income per diluted share. Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP measure are included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the impact of foreign exchange, the Company converts actual current-period net sales from local currency to U.S. dollars using constant foreign exchange rates. The GAAP measure most comparable to this non-GAAP measure is growth rate percentages based on GAAP revenue. A reconciliation of this non-GAAP financial measure to the corresponding GAAP measure is included in the accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston Scientific

Management uses these supplemental non-GAAP measures to evaluate performance period over period, to analyze the underlying trends in the Company's business, to assess its performance relative to its competitors, and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP measures to further its understanding of the performance of the Company's operating segments. The adjustments excluded from the Company's non-GAAP measures are consistent with those excluded from its reportable segments' measure of profit or loss. These adjustments are excluded from the segment measures that are reported to the Company's chief operating decision maker and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management excluded as part of its non-GAAP measures for the three and nine month periods ending September 30, 2008 and September 30, 2007 and for the forecasted three month period ending December 31, 2008, as well as reasons for excluding each of these individual items:

-- Acquisition-related (credits) charges - These adjustments primarily

consist of a gain resulting from the receipt of an acquisition-related

milestone payment, purchased research and development, integration

costs associated with the Company's acquisition of Guidant, and a fair

value adjustment related to the sharing of proceeds feature of the

Abbott stock purchase. The acquisition-related milestone payment is one

of two payments the Company expects to receive as a result of Guidant's

sale of its vascular intervention and endovascular solutions businesses

to Abbott and are not indicative of future operating results. Purchased

research and development is a highly variable charge based on valuation

assumptions. Management removes the impact of purchased research and

development from the Company's operating results to assist in assessing

the Company's operating performance and cash generated from operations.

The integration costs associated with the Company's acquisition of

Guidant do not reflect expected on-going future operating expenses. The

fair value adjustment related to the sharing of proceeds feature of the

Abbott stock purchase is a non-cash adjustment and is not indicative of

the Company's on-going operations. Accordingly, management excluded

these charges and gains for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance and a comparison to the Company's past operating

performance.

-- Restructuring-related charges - These adjustments primarily represent

severance, employee-related retention incentives, asset write-offs and

accelerated depreciation and other costs associated with the Company's

restructuring initiatives. These expenses are not indicative of the

Company's on-going operating performance and are excluded by management

in assessing the Company's operating performance, and are also excluded

from the Company's operating segments' measures of profit and loss used

for making operating decisions and assessing performance. Accordingly,

management excluded these charges for purposes of calculating these

non-GAAP measures to facilitate an evaluation of the Company's current

operating performance and a comparison to the Company's past operating

performance.

-- Litigation-related charges - These charges are attributable to

estimated potential losses associated with patent litigation. These

amounts represent significant charges during the third quarter of 2008

and do not reflect expected on-going operating expenses. Accordingly,

management excluded these charges for purposes of calculating these

non-GAAP measures to facilitate an evaluation of the Company's current

operating performance and for comparison to the Company's past

operating performance.

-- Divestiture-related (gains) losses - These amounts represent gains and

losses, and related tax impacts, that the Company recognized related to

the sale of non-strategic assets, including the sale of certain

businesses, development programs and non-strategic investments. The

sale and transfer of these non-strategic assets are expected to be

substantially completed during 2008. These gains and losses are not

indicative of future operating performance and are not used by

management to assess operating performance. Accordingly, management

excluded these amounts for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance and a comparison to the Company's past operating

performance.

-- Intangible asset impairment charges - These amounts represent non-cash

write-downs of certain of the Company's intangible assets. Following

the Company's acquisition of Guidant, and the related increase in the

Company's debt, management has heightened its focus on cash generation

and debt pay down. Management removes the impact of these charges from

the Company's operating performance to assist in assessing the

Company's cash generated from operations. Management believes this is a

critical metric for the Company in measuring the Company's ability to

generate cash and pay down debt. Therefore, these charges are excluded

from management's assessment of operating performance and are also

excluded from the measures management uses to set employee

compensation. Accordingly, management believes this may be useful

information to users of its financial statements and therefore has

excluded these charges for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance, particularly in terms of liquidity.

-- Amortization expense - Amortization expense is a non-cash charge and

does not impact the Company's liquidity or compliance with the

covenants included in its debt agreements. Management removes the

impact of amortization from the Company's operating performance to

assist in assessing the Company's cash generated from operations.

Management believes this is a critical metric for the Company in

measuring the Company's ability to generate cash and pay down debt.

Therefore, amortization expense is excluded from management's

assessment of operating performance and is also excluded from the

measures management uses to set employee compensation. Accordingly,

management believes this may be useful information to users of its

financial statements and therefore has excluded amortization expense

for purposes of calculating these non-GAAP measures to facilitate an

evaluation of the Company's current operating performance, particularly

in terms of liquidity.

-- Foreign exchange on net sales - The impact of foreign exchange is

highly variable and difficult to predict. Accordingly, management

excludes the impact of foreign exchange for purposes of reviewing

regional and divisional revenue growth rates to facilitate an

evaluation of the Company's current operating performance and

comparison to the Company's past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial Measures

Non-GAAP net income, non-GAAP net income per diluted share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange may have limitations as analytical tools, and these non-GAAP measures should not be considered in isolation from or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are:

-- Items such as purchased research and development, divestiture-related

gains and losses, gains on acquisition-related milestones and the fair

value adjustment related to the sharing of proceeds feature of the

Abbott stock purchase reflect economic costs to the Company and are not

reflected in non-GAAP net income and non-GAAP net income per diluted

share.

-- Items such as Guidant integration costs and restructuring-related

expenses that are excluded from non-GAAP net income and non-GAAP net

income per diluted share can have a material impact on cash flows and

GAAP net income and net income per diluted share.

-- Items such as amortization expense and intangible asset impairment

charges, though not directly affecting Boston Scientific's cash flow

position, represent a reduction in value of intangible assets over

time. The expense associated with this reduction in value is not

included in Boston Scientific's non-GAAP net income or non-GAAP net

income per diluted share and therefore these measures do not reflect

the full economic effect of the reduction in value of those intangible

assets.

-- Revenue growth rates stated on a constant currency basis, by their

nature, exclude the impact of foreign exchange, which may have a

material impact on GAAP net sales.

-- Other companies may calculate non-GAAP net income, non-GAAP net income

per diluted share, or regional and divisional revenue growth rates that

exclude the impact of foreign exchange differently than Boston

Scientific does, limiting the usefulness of those measures for

comparative purposes.

Compensation for Limitations Associated with Use of Non-GAAP Financial Measures

Boston Scientific compensates for the limitations on its non-GAAP financial measures by relying upon its GAAP results to gain a complete picture of the Company's performance. The non-GAAP numbers focus instead upon the core business of the Company, which is only a subset, albeit a critical one, of the Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial measure to its most directly comparable GAAP measure in the accompanying schedules, and Boston Scientific encourages investors to review these reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income, non-GAAP net income per share, and regional and divisional revenue growth rates that exclude the impact of foreign exchange in addition to the related GAAP measures provides investors greater transparency to the information used by Boston Scientific management for its financial and operational decision-making and allows investors to see Boston Scientific's results "through the eyes" of management. The Company further believes that providing this information better enables Boston Scientific's investors to understand the Company's operating performance and to evaluate the methodology used by management to evaluate and measure such performance.

ded Johnson & Johnson-related litigation charges, acquisition- and divestiture-related net credits, restructuring-related charges, intangible asset impairments and amortization expense (after-tax) of $298 million, or approximately $0.20 per share, which consisted of the following:

-- $334 million of pre-tax charges ($266 million after-tax) resulting from

a ruling by a federal judge in a patent infringement case brought

against the Company by Johnson & Johnson;

-- $250 million pre-tax gain ($184 million after-tax) related to the

receipt of an acquisition-related milestone payment from Abbott

Laboratories;

-- $8 million credit, on both a pre-tax and after-tax basis, to purchased

research and development associated with the Company's acquisition of

CryoCor, Inc.;

-- $15 million of pre-tax net gains ($9 million after-tax) in connection

with the sale of the Company's non-strategic investments;

-- $17 million of income tax benefit associated with the Company's

previous sale of non-strategic businesses;

-- $34 million of pre-tax charges ($25 million after-tax) associated with

the Company's ongoing expense and head count reduction initiatives;

-- $155 million of pre-tax intangible asset impairment charges ($129

million after-tax); and

-- $131 million of pre-tax amortization expense ($96 million after-tax).

Adjusted net income for the quarter, excluding these amounts, was $236 million, or $0.16 per share.

Reported net loss for the third quarter of 2007 was $272 million, or $0.18 per share. Reported results for the third quarter of 2007 included acquisition- and divestiture-related charges and amortization expense (after-tax) of $571 million, or approximately $0.38 per share. Adjusted net income for the third quarter of 2007, excluding these charges, was $299 million, or $0.20 per share.

Guidance for Fourth Quarter 2008

The Company estimates net sales for the fourth quarter of 2008 of between $1.965 billion and $2.080 billion. Adjusted EPS, excluding restructuring-related charges and amortization expense, is estimated to range between $0.18 and $0.23 per share. The Company estimates reported EPS on a GAAP basis of between $0.10 and $0.15 per share. Included in the Company's estimated reported EPS on a GAAP basis is $0.01 per share of restructuring-related charges and $0.07 per share of amortization expense.

Boston Scientific management will be discussing these results with analysts on a conference call at 8:00 a.m. (ET) Wednesday, October 22, 2008. The Company will webcast the call to all interested parties through its website: http://www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one year on the Boston Scientific website.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our programs to increase shareholder value, new product approvals, acquisitions and divestitures, our growth strategy, competitive offerings and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release.

CONTACT:

Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS

(Unaudited)

Three Months Ended

September 30,

In millions, except per share data 2008 2007

Net sales $1,978 $2,048

Cost of products sold 655 575

Gross profit 1,323 1,473

Operating expenses

Selling, general and administrative

expenses 610 719

Research and development expenses 252 271

Royalty expense 51 48

Amortization expense 131 155

Intangible asset impairment charges 155

Purchased research and development (8) 75

Litigation-related charges 334

Restructuring charges 20

Acquisition-related milestone (250)

Loss on assets held for sale 352

1,295 1,620

Operating income (loss) 28 (147)

Other income (expense):

Interest expense (112) (147)

Other, net 16 35

Loss before income taxes (68) (259)

Income tax (benefit) expense (6) 13

Net loss $(62) $(272)

Net loss per common share - basic $(0.04) $(0.18)

Net loss per common share - assuming

dilution $(0.04) $(0.18)

Weighted average shares outstanding -

basic 1,500.9 1,489.8

Weighted average shares outstanding -

assuming dilution 1,500.9 1,489.8

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

Three Months Ended Three Months Ended

September 30, 2008 September 30, 2007

Impact per Impact per

In millions, except per Net (loss) diluted Net (loss) diluted

share data income share income share

GAAP results $(62) $(0.04) $(272) $(0.18)

Non-GAAP adjustments:

Acquisition-related (credits)

charges (192) (0.13) 83 0.06

Restructuring-related charges 25 0.02

Litigation-related charges 266 0.18*

Divestiture-related (gains)

losses (26) (0.02)* 352 0.23*

Intangible asset impairment

charges 129 0.09*

Amortization expense 96 0.06* 136 0.09*

Adjusted results $236 $0.16 $299 $0.20

* Assumes dilution of 7.0 million shares for the quarter ended September

30, 2008 and 12.5 million shares for the quarter ended September 30,

2007 for all or a portion of these non-GAAP adjustments.

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(CONT.)

(Unaudited)

Three Months Ended

September 30,

2008 2007

Acquisition-related (credits) charges:

Acquisition-related milestone $(250)

Purchased research and development (8) $75

Integration costs (a) 10

(258) 85

Income tax expense (benefit) (d) 66 (2)

Acquisition-related (credits) charges, net of tax $(192) $83

Restructuring-related charges:

Restructuring-related charges (b) $34

Income tax benefit (d) (9)

Restructuring-related charges, net of tax $25

Litigation-related charges:

Litigation-related charges $334

Income tax benefit (d) (68)

Litigation-related charges, net of tax $266

Divestiture-related (gains) losses:

Gain on sale of investments (c) $(15)

Loss on assets held for sale $352

(15) 352

Income tax benefit (d) (11)

Divestiture-related (gains) losses, net of tax $(26) $352

Intangible asset impairment charges:

Intangible asset impairment charges $155

Income tax benefit (d) (26)

Intangible asset impairment charges, net of tax $129

Amortization expense:

Amortization expense $131 $155

Income tax benefit (d) (35) (19)

Amortization expense, net of tax $96 $136

(a) Recorded $8 million to selling, general and administrative expenses

and $2 million to cost of products sold.

(b) Recorded $4 million to cost of products sold; $9 million to selling,

general and administrative expenses; $1 million to research and

development expenses; and $20 million to restructuring charges.

(c) Recorded to other, net.

(d) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item in

accordance with FASB Interpretation No. 18, "Accounting for Income

Taxes in Interim Periods."

An explanation of the Company's use of these non-GAAP measures is provided at the end of this document.


'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
2. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
3. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
4. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
5. Boston Scientific to Participate in UBS Global Life Sciences Conference
6. Boston Scientific Announces Court Decision
7. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
10. TechCFO Adds Gary Strickland as Partner in Boston Office
11. Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
(Date:12/8/2016)... Worcester, Mass (PRWEB) , ... December 08, 2016 ... ... KbioBox genetic data bioInformatics portal. In response to client demand KbioBox developed a ... gene edit biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we ... of recovery so we need to do it well. Inadequate sleep levels have been ... blood pressure, stroke, diabetes, and even cancer. Maybe now is the best ... that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):